CITIGROUP PIPER JAFFRAYUnderwriting Agreement • May 10th, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • New York
EXHIBIT 10.17 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. LICENSE AGREEMENT This Licensing Agreement (the "Agreement") is made effective the 1st day of March, 2002 (the...License Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • District of Columbia
EXHIBIT 10.5Registration Rights Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Massachusetts
Exhibit 10.2 ALNYLAM PHARMACEUTICALS, INC. Restricted Stock Agreement Granted Under 2004 Stock Incentive Plan AGREEMENT made this 12th day of July, 2005, between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), and James L....Restricted Stock Agreement • July 13th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
EXHIBIT 1.1 4,700,000 SHARES ALNYLAM PHARMACEUTICALS, INC. Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT December 12, 2006Underwriting Agreement • December 13th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
EXHIBIT 10.11 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (THIS "AGREEMENT") dated as of December 18, 2002, between SILICON VALLEY BANK, a California chartered bank, with its principal place of business at 3003 Tasman Drive, Santa...Loan and Security Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Delaware
ANDStock Purchase Agreement • September 12th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
Exhibit 10.13 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION...Alnylam Pharmaceuticals Inc • February 27th, 2004 • Massachusetts
ALNYLAM PHARMACEUTICALS, INC. 5,600,000 Shares of Common Stock Underwriting AgreementAlnylam Pharmaceuticals, Inc. • November 14th, 2017 • Pharmaceutical preparations • New York
Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule I hereto (the “Underwriters”), for whom Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as representatives (the “Representatives”), an aggregate of 5,600,000 shares of common stock, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 840,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ANDLicense Agreement • November 9th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
LEASEAlnylam Pharmaceuticals Inc • February 27th, 2004 • Massachusetts
ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 15, 2022 1.00% Convertible Senior Notes due 2027Indenture • September 16th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
INDENTURE dated as of September 15, 2022 between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
RECITALS:Alnylam Pharmaceuticals, Inc. • May 9th, 2006 • Pharmaceutical preparations
BY AND BETWEENLicense Agreement • March 2nd, 2009 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
EXHIBIT 10.19 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. CO-EXCLUSIVE LICENSE AGREEMENT between Garching Innovation GmbH, Hofgartenstrasse 8, 80539 Munchen, Germany,...License Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations
ANDCollaboration Agreement • May 16th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
FORM OF DIRECTOR INDEMNIFICATION AGREEMENTIndemnification Agreement • August 4th, 2016 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
EXHIBIT 10.23 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. SPONSORED RESEARCH AGREEMENT Effective as of 1 OCTOBER 2003, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH,...Research Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • Mayo
BY AND AMONGCollaboration and License Agreement • August 4th, 2006 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
ALNYLAM PHARMACEUTICALS, INC. AND THE BANK OF NEW YORK MELLON, as Trustee INDENTURE Dated as of September 15, 2022 1.00% Convertible Senior Notes due 2027Alnylam Pharmaceuticals, Inc. • October 27th, 2022 • Pharmaceutical preparations • New York
INDENTURE dated as of September 15, 2022 between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and THE BANK OF NEW YORK MELLON, a New York banking corporation, as trustee (the “Trustee,” as more fully set forth in Section 1.01).
ALNYLAM PHARMACEUTICALS, INC LICENCE AGREEMENTLicence Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • London
EXHIBIT 10.18 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS. LICENSE AGREEMENT This License Agreement (this "Agreement"), is effective December 30, 2003 (the "Effective...License Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • New York
LEASE by and between BMR-675 WEST KENDALL STREET LLC, a Delaware limited liability company and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporationLease • August 7th, 2015 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and Term Expiration Date as of the date first written above.
Exhibit 10.12 NEITHER THIS WARRANT NOR THE PREFERRED STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "1933 ACT"), OR ANY APPLICABLE STATE SECURITIES LAWS, AND NEITHER THIS WARRANT NOR...Alnylam Pharmaceuticals Inc • April 6th, 2004 • Pharmaceutical preparations • Delaware
ALNYLAM PHARMACEUTICALS, INC. and Trustee INDENTURE Dated as of _______________ SUBORDINATED DEBT SECURITIESIndenture • July 21st, 2011 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
WHEREAS, the Issuer may from time to time duly authorize the issue of its unsecured subordinated debentures, notes or other evidences of indebtedness to be issued in one or more series (the “Securities”) up to such principal amount or amounts as may from time to time be authorized in accordance with the terms of this Indenture;
EXHIBIT 10.12 UNCONDITIONAL GUARANTY For and in consideration of certain loans by SILICON VALLEY BANK, a California-chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production...Alnylam Pharmaceuticals Inc • February 27th, 2004
RECITALSLoan and Security Agreement • April 6th, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • California
EXHIBIT 10.2 VIA HAND DELIVERY October 9, 2006 Vincent J. Miles, Ph.D. 62 Woodchester Drive Chestnut Hill, MA 02467 Dear Vin: This letter agreement sets forth the terms of your continued employment with Alnylam Pharmaceuticals, Inc. (the "Company")....Alnylam Pharmaceuticals, Inc. • November 9th, 2006 • Pharmaceutical preparations • Massachusetts
EXECUTION INVESTOR RIGHTS AGREEMENT THIS INVESTOR RIGHTS AGREEMENT (the "AGREEMENT") is entered into as of September 8, 2003 by and between Alnylam Holding Co., a Delaware corporation (the "CORPORATION"), and Merck & Co., Inc., a New Jersey...Investor Rights Agreement • February 27th, 2004 • Alnylam Pharmaceuticals Inc • Delaware
BY AND AMONGResearch Collaboration and License Agreement • May 21st, 2004 • Alnylam Pharmaceuticals Inc • Pharmaceutical preparations • New York
DATE: September [ ], 2022 TO: Alnylam Pharmaceuticals, Inc. 675 West Kendall Street, Henri A. Termeer Square Cambridge, Massachusetts 02142 FROM: [Insert Dealer Name] SUBJECT: [Base][Additional] Call Option TransactionAlnylam Pharmaceuticals, Inc. • September 16th, 2022 • Pharmaceutical preparations
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer] (“Dealer”) and Alnylam Pharmaceuticals, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
EXHIBIT 10.3 ALNYLAM PHARMACEUTICALS, INC. Incentive Stock Option Agreement Granted Under 2004 Stock Incentive Plan 1. Grant of Option. This agreement evidences the grant by Alnylam Pharmaceuticals, Inc., a Delaware corporation (the "Company"), on...Alnylam Pharmaceuticals, Inc. • August 11th, 2005 • Pharmaceutical preparations
ANDInvestor Rights Agreement • September 12th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
CREDIT AGREEMENT Dated as of April 29, 2016 Among ALNYLAM U.S., INC., as the Borrower, ALNYLAM PHARMACEUTICALS, INC., as Parent and Parent Guarantor, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as the LenderCredit Agreement • August 4th, 2016 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This CREDIT AGREEMENT is entered into as of April 29, 2016, among ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (the “Parent” or the “Parent Guarantor”), ALNYLAM U.S., INC., a Delaware corporation and a wholly-owned Subsidiary of Parent (the “Borrower” and, together with the Parent Guarantor, collectively the “Loan Parties” and, each individually, a “Loan Party”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, as the Lender.
BETWEENRights Agreement • July 14th, 2005 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
